Ken Saijo

727 total citations
47 papers, 530 citations indexed

About

Ken Saijo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ken Saijo has authored 47 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Ken Saijo's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Ken Saijo is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Histone Deacetylase Inhibitors Research (6 papers). Ken Saijo collaborates with scholars based in Japan, Canada and Greece. Ken Saijo's co-authors include Chikashi Ishioka, Hidekazu Shirota, Hiroo Imai, Hideki Shimodaira, Tadashi Katoh, Masanobu Takahashi, Keigo Komine, Shin Takahashi, Masahiro Takahashi and Akifumi Oda and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ken Saijo

43 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ken Saijo Japan	12	232	203	133	92	68	47	530
Donald Poon Singapore	12	224 1.0×	256 1.3×	131 1.0×	105 1.1×	86 1.3×	19	688
Leung Li Hong Kong	14	209 0.9×	132 0.7×	104 0.8×	109 1.2×	58 0.9×	33	571
E Popa United States	11	238 1.0×	191 0.9×	158 1.2×	122 1.3×	12 0.2×	28	682
Keigo Komine Japan	14	295 1.3×	155 0.8×	151 1.1×	107 1.2×	25 0.4×	53	585
Roland Kurdow Germany	11	224 1.0×	167 0.8×	395 3.0×	253 2.8×	37 0.5×	22	699
Sanders Chang United States	11	114 0.5×	138 0.7×	74 0.6×	109 1.2×	21 0.3×	25	417
Joaquina Martínez-Galán Spain	14	257 1.1×	236 1.2×	124 0.9×	81 0.9×	49 0.7×	36	544
Hajime Yokomizo Japan	12	282 1.2×	59 0.3×	129 1.0×	241 2.6×	18 0.3×	121	512
Peiliang Quan China	12	204 0.9×	122 0.6×	119 0.9×	175 1.9×	25 0.4×	25	496
Lee Schwartzberg United States	8	333 1.4×	113 0.6×	133 1.0×	53 0.6×	8 0.1×	17	603

Countries citing papers authored by Ken Saijo

Since Specialization

Citations

This map shows the geographic impact of Ken Saijo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Saijo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Saijo more than expected).

Fields of papers citing papers by Ken Saijo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Saijo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Saijo. The network helps show where Ken Saijo may publish in the future.

Co-authorship network of co-authors of Ken Saijo

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Saijo. A scholar is included among the top collaborators of Ken Saijo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Saijo. Ken Saijo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saijo, Ken, et al.. (2025). Immune Checkpoint Inhibitors in Sinonasal Squamous Cell Carcinoma: A Retrospective Study and Literature Review. Cancers. 17(17). 2872–2872.

Takahashi, Masanobu, Keigo Komine, Kota Ouchi, et al.. (2025). Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database. International Journal of Clinical Oncology. 30(5). 914–925. 1 indexed citations

Takahashi, Masanobu, Keigo Komine, Hideki Tokunaga, et al.. (2025). Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome who had uterine and ovarian cancer. International Cancer Conference Journal. 14(2). 171–176.

Koseki, Yoshitaka, Sanjay Kumar, Hirotaka Nakatsuji, et al.. (2024). Carrier-free nano-prodrugs for minimally invasive cancer therapy. Nanoscale. 16(32). 15256–15264. 4 indexed citations

Imai, Hiroo, et al.. (2024). Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer. Internal Medicine. 63(19). 2667–2671. 1 indexed citations

Shibata, Hirofumi, et al.. (2024). Immune-Modified Glasgow Prognostic Score Predicts Therapeutic Effect of Pembrolizumab in Recurrent and Metastatic Head and Neck Cancer. Cancers. 16(23). 4056–4056.

Saijo, Ken, Kota Ouchi, Keigo Komine, et al.. (2024). Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab. Scientific Reports. 14(1). 28255–28255. 2 indexed citations

Ouchi, Kota, Shin Takahashi, Keigo Komine, et al.. (2024). Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial. International Journal of Colorectal Disease. 39(1). 89–89. 2 indexed citations

Saijo, Ken, Hiroo Imai, Kota Ouchi, et al.. (2023). Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens. Frontiers in Oncology. 13. 1230731–1230731. 3 indexed citations

10.

Komine, Keigo, Yoshifumi Kawamura, Kota Ouchi, et al.. (2023). FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma. Anticancer Research. 43(12). 5699–5704. 3 indexed citations

11.

Imai, Hiroo, Ken Saijo, Keigo Komine, et al.. (2022). Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study. SHILAP Revista de lepidopterología. 7 indexed citations

12.

Kawamura, Yoshifumi, Ken Saijo, Hiroo Imai, & Chikashi Ishioka. (2021). Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells. Cancer Science. 112(11). 4711–4721. 6 indexed citations

13.

Hiratsuka, Yusuke, Takayuki Oishi, Mitsunori Miyashita, et al.. (2021). Factors related to specialized palliative care use and aggressive care at end of life in Japanese patients with advanced solid cancers: a cohort study. Supportive Care in Cancer. 29(12). 7805–7813. 4 indexed citations

14.

Tahara, Makoto, Naomi Kiyota, Tomoya Yokota, et al.. (2018). Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Annals of Oncology. 29(4). 1004–1009. 65 indexed citations

15.

Saijo, Ken, et al.. (2017). Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3‐kinase dual inhibitor. Cancer Science. 108(7). 1469–1475. 13 indexed citations

16.

Shirota, Hidekazu, et al.. (2017). IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunology Immunotherapy. 66(11). 1485–1496. 60 indexed citations

17.

Imai, Hiroo, Keigo Komine, Shin Takahashi, et al.. (2016). Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma. Chemotherapy. 61(5). 262–268. 10 indexed citations

18.

Sugiyama, Shunsuke, Masanobu Takahashi, Keigo Komine, et al.. (2016). Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs. International Cancer Conference Journal. 5(4). 163–167.

19.

Oda, Akifumi, Ken Saijo, Chikashi Ishioka, et al.. (2014). Predicting the structures of complexes between phosphoinositide 3-kinase (PI3K) and romidepsin-related compounds for the drug design of PI3K/histone deacetylase dual inhibitors using computational docking and the ligand-based drug design approach. Journal of Molecular Graphics and Modelling. 54. 46–53. 11 indexed citations

20.

Saijo, Ken, Tadashi Katoh, Hideki Shimodaira, et al.. (2012). Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3‐kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3‐kinase dual inhibitors. Cancer Science. 103(11). 1994–2001. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact